In the twelve months that make up 2022, Drugs targeted for diabetes and cardiovascular diseases have been the most billed drugs in Spanish pharmacies, Notably, five antidiabetic treatments, three antithrombotics, one for osteoporosis and another for heart failure lead the rankings, according to data from consultancy Equivia.
Top of the list is Eliquis, an anticoagulant from the pharmaceutical company Bristol Myers Squibb. By May 2022, the latest data known, the drug recorded sales of 118.6 million euros, a 17.1% increase over the previous year in Spanish pharmacies. It was followed by Novo Nordisk’s Ozempic with €83.40 million, Bayer’s Xarelto with €80.40 million, Lilly’s Trulicity with €64.30 million and Boehringer’s Jardiance with €57.40 million.
The treatment that ranks second is that of a Danish company; And the fourth position, the US company, suffers from the problem of supply due to demand. In October 2022, the Spanish Agency for Medicines and Health Products (AEMPS) collaborated with both companies Warns about shortage of both drugs, along with AstraZeneca’s Bydureon, to launch new treatments for both 2022 and 2023. He asked health professionals not to start new treatments with these drugs
from fifth place, Many drugs have changed the situation, At number six is Prolia, an anticoagulant from pharmaceutical company Amgen (the company recently acquired Ireland’s Horizon Therapeutics), which has risen two positions since May. In the first five months of 2022, it made a bill of 50.50 crores. It is followed by Daiichi Sankyo Co’s Lixiana, which recorded sales of 58.60 million till May. It has since dropped two places.
These are not the only drugs that have had varying positions in the rankings. Novartis Entresto is currently ranked eighth, one higher than it was in the first five months of 2022. By then, it had a turnover of 53.10 million euros. It was followed by Synjardy, marketed by Boehringer and Lilly, in ninth place, which recorded sales of 45.70 million by May of that year. Since that time diabetes medicine has moved up a notch.
Last on the list is Toujeo from Sanofi, a drug for diabetes. By May 2022 it had done a business of 46.30 million euros and was ranked ninth in the rankings. Whereas, as far as the signs are concerned, Bristol Myers Squibb’s drug tops the list for those targeting anticoagulants and Novo Nordisk’s is prescribed for diabetes.,